BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

...Euronext:SAN; NASDAQ:SNY) said late Friday that FDA issued a complete response letter to a BLA for anti-C1s...
...reuptake inhibitors to treat CNS disorders associated with anxiety, mood and stress-related disorders. BC Staff sutimlimab (BIVV009, tnt009) Sanofi Complement component 1 s subcomponent (C1S) Hematology Anemia...
BioCentury | Nov 13, 2020
Emerging Company Profile

Kira: overcoming the complexities of complement

...C5 and C1, a five-unit complex containing two units each of the esterases C1r and C1s. Four...
...esterase and C5 in clinical development, according to BioCentury’s BCIQ database. Two are in registration: IV-administered anti-C1s...
...and Sinopharm CapitalCEO: Frederick BeddingfieldPatents: UndisclosedTARGETSC1q – Complement component 1 q subcomponentC1r – Complement C1r C1s...
BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

...BLA for sutimlimab to treat hemolysis in adults with cold agglutinin disease. If approved the anti-C1s...
...to SOC Truvada emtricitabine/tenofovir in the Phase IIb/III HPTN 083 trial for HIV prevention. Targets C1s...
...Staff Lava Therapeutics B.V. ViiV Healthcare Ltd. Janssen Pharmaceuticals ? Johnson & Johnson Johnson & Johnson Innovation ? JJDC Sanofi Zai Lab Ltd. Complement component 1 s subcomponent (C1S)...
BioCentury | Nov 23, 2019
Clinical News

A first-in-class approval for rare anemia could be next step for Sanofi’s sutimlimab

...antibody binding of red blood cells and triggers erythrocyte destruction. Sanofi (Euronext:SAN: NYSE:SNY) gained the anti-C1s...
...activity while preserving immunoprotection mediated by other complement activation mechanisms: the lectin and alternative pathways. C1s...
...therapy designation from FDA and Orphan Disease designation in the U.S., EU and Japan. Targets: C1s...
BioCentury | Jan 27, 2018
Strategy

Growing up Genzyme

...attached to Factor VIII and von Willebrand factor (vWF). BIVV009 is a humanized mAb against complement component 1 s subcomponent (C1S)...
BioCentury | Jan 26, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...acquisition last year of True North Therapeutics Inc. The therapy is a humanized mAb against complement component 1 s subcomponent (C1S)...
...Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North Therapeutics Inc. Complement component 1 s subcomponent (C1S)...
BioCentury | Jan 22, 2018
Company News

Sanofi acquiring Bioverativ for $11.6B

...acquisition last year of True North Therapeutics Inc. The therapy is a humanized mAb against complement component 1 s subcomponent (C1S)...
...within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Biogen Inc. Bioverativ Inc. Sanofi True North Therapeutics Inc. Anti-thrombin III (AT3) (SERPINC1) Complement component 1 s subcomponent (C1S)...
BioCentury | May 26, 2017
Company News

Bioverativ aquiring True North

...front and are eligible for $425 million in milestones. TNT009 is a humanized mAb against complement component 1 s subcomponent (C1S)...
...South San Francisco, Calif. Bioverativ Inc. (NASDAQ:BIVV), Cambridge, Mass. Business: Hematology Shannon Lehnbeuter TNT009 Bioverativ Inc. True North Therapeutics Inc. Complement component 1 s subcomponent (C1S)...
BioCentury | May 26, 2017
Finance

Fast cash

...the milestones are undisclosed. True North’s lead asset, TNT009 , is a humanized mAb against complement component 1 s subcomponent (C1S)...
BioCentury | May 23, 2017
Company News

Bioverativ acquiring True North

...front and are eligible for $425 million in milestones. TNT009 is a humanized mAb against complement component 1 s subcomponent (C1S)...
...close in mid-2017. Bioverativ slipped $2.19 to $52.50 on Tuesday. Becky Simon TNT009 Biogen Inc. Bioverativ Inc. True North Therapeutics Inc. Complement component 1 s subcomponent (C1S) Anemia...
Items per page:
1 - 10 of 22